Accuray Incorporated said it has entered into agreements with Samsung HME America, Inc., which does business as NeuroLogica Corp., to pursue advanced volumetric imaging capabilities for the CyberKnife System. The announcement coincides with the American Society of Radiation Oncology annual meeting in Boston, Massachusetts, where the two companies are highlighting the collaboration.
Accuray said its customers have consistently identified imaging capabilities that enhance treatment efficiency and support informed decision-making as important priorities. Under the collaboration, Samsung NeuroLogica's experience in mobile computed tomography and volumetric imaging is to be coupled with Accuray's work in precision treatment delivery, robotic radiosurgery and motion management. Accuray described the arrangement as one part of a strategy to address customer priorities through targeted partnerships.
Professor Nicholas van As, a consultant clinical oncologist at The Royal Marsden NHS Foundation Trust, said that seeing the target and surrounding anatomy together at the time of treatment could help clinicians make more informed decisions for each patient, and that The Royal Marsden is the first centre worldwide to take part in the collaboration. Jonathan Lischalk, clinical director of radiosurgery at MedStar Georgetown University Hospital, said the potential of volumetric imaging alongside robotic radiosurgery extends across thoracic, abdominal and pelvic malignancies, and that he is scheduled to speak at Accuray's clinical session at the meeting on Monday, September 28.
Boris Geyzer, head of business for mobile CT at Samsung HME America, said the discussion with Accuray begins with a practical clinical need for better visualisation of anatomy in the treatment room. Accuray said the collaboration will progress through phased development activities while the companies evaluate technical, clinical and commercial opportunities. No commercial product offering has been announced, and future developments remain subject to ongoing evaluation and applicable regulatory requirements, the company said.
